本文言語 | English |
---|---|
ページ(範囲) | 8235-8236 |
ページ数 | 2 |
ジャーナル | Annals of Surgical Oncology |
巻 | 29 |
号 | 13 |
DOI |
|
出版ステータス | Published - 2022 12月 |
ASJC Scopus subject areas
- 外科
- 腫瘍学
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Surgical Oncology, Vol. 29, No. 13, 12.2022, p. 8235-8236.
研究成果: Comment/debate › 査読
}
TY - JOUR
T1 - ASO Author Reflections
T2 - Epidural Analgesia Decreases In-Hospital Mortality, Respiratory Complications, and Anastomotic Leakage After Minimally Invasive Esophagectomy for Esophageal Cancer
AU - Hirano, Yuki
AU - Kaneko, Hidehiro
AU - Konishi, Takaaki
AU - Itoh, Hidetaka
AU - Matsuda, Satoru
AU - Kawakubo, Hirofumi
AU - Daiko, Hiroyuki
AU - Itano, Osamu
AU - Yasunaga, Hideo
AU - Kitagawa, Yuko
N1 - Funding Information: Dr. Kitagawa has received grants and personal fees from Asahi Kasei Pharma Corporation, grants, personal fees and others from Ono Pharmaceutical Co. Ltd., grants and personal fees from Otsuka Pharmaceutical Factory Inc., grants and personal fees from Nippon Covidien Inc., grants, personal fees and others from Taiho Pharmaceutical Co. Ltd., grants, personal fees and others from Chugai Pharmaceutical Co. Ltd., grants and personal fees from Kaken Pharmaceutical Co. Ltd., personal fees from AstraZeneca K.K., personal fees from Ethicon Inc., personal fees from Olympus Corporation, personal fees from Shionogi & Co. Ltd., personal fees and others from Bristol-Myers Squibb K.K., personal fees from MSD K.K., personal fees from Smith & Nephew K.K., personal fees from Aska Pharmaceutical Co. Ltd., personal fees from Miyarisan Pharmaceutical Co. Ltd., personal fees from Toray Industries, Inc., personal fees from Daiichi Sankyo Co. Ltd., personal fees from Chugai Foundation for Innovative Drug Discovery Science, personal fees from Nippon Kayaku Co. Ltd., grants from Yakult Honsha Co. Ltd., grants from Otsuka Pharmaceutical Co. Ltd., grants from Tsumura & Co., grants from Sumitomo Pharma Co. Ltd., grants from EA Pharma Co. Ltd., grants from Eisai Co. Ltd., grants from Kyouwa Hakkou Kirin Co. Ltd., grants from Medicon Inc., grants from Takeda Pharmaceutical Co. Ltd., and grants from Teijin Pharma Ltd. outside the submitted work. No other disclosures are reported. Funding Information: This work was supported by grants from the Ministry of Health, Labour and Welfare, Japan (21AA2007 and 20AA2005) and the Ministry of Education, Culture, Sports, Science, and Technology, Japan (20H03907).
PY - 2022/12
Y1 - 2022/12
UR - http://www.scopus.com/inward/record.url?scp=85137210226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137210226&partnerID=8YFLogxK
U2 - 10.1245/s10434-022-12431-1
DO - 10.1245/s10434-022-12431-1
M3 - Comment/debate
C2 - 36029380
AN - SCOPUS:85137210226
SN - 1068-9265
VL - 29
SP - 8235
EP - 8236
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 13
ER -